Thank you, Rutuja. Good evening, everyone, and thank you for joining us on Rossari Biotech Limited's Q4 and FY '26 earnings conference call.

We have with us Mr. Edward Menezes, Promoter and Executive Chairman; Mr.

Sunil Chari, Promoter and Managing Director; and Mr. Ketan Sablok, Group Chief Financial Officer of the company.

We will begin the call with opening remarks from the management, following which we will have the forum open for a question-and-answer session. Before we start, I would like to point out that some statements made in today's call may be forward-looking in nature, and a disclaimer to this effect has been included in the earnings presentation shared with you all earlier.

I would now like to invite Mr. Edward Menezes to make his opening remarks.

Thank you, and over to you, sir.

Thank you, Mitesh. Good evening, everyone, and thank you for joining us on our earnings conference call.

It is a pleasure to have you with us as we discuss our operational and financial performance for the quarter and the full year ended March 31, 2026. We concluded the year '26 on a very strong note with Q4 marking our highest ever quarterly revenue and EBITDA performance.

For the full year, we delivered revenue growth of 15%, which was primarily volume-driven. Performance during the year was supported by healthy traction across businesses and steady progress in the international markets.

While the year saw its share of external challenges, including volatility in certain raw materials markets and disruptions arising from geopolitical developments in the Middle East, the business remained resilient, with all our key segments delivering healthy growth during the quarter. A key area of focus for us continues to be R&D and innovation.

We are gradually evolving from a formulation-led approach towards developing broader platform technologies with multi-vertical applicability, enabling more scalable and differentiated solutions across end-user segments. During the year, this translated into meaningful progress in product development and application-led innovation, with newer products contributing increasingly to the business and sustainable chemistries, including biosurfactants, gaining traction.

To further strengthen this capability, we set up a new R&D facility in Navi Mumbai, which brings together our existing R&D operations, including the IIT Mumbai Center under one roof. We expect this facility to provide a stronger platform for innovation, product development, and application-led research, while also improving collaboration and supporting faster scale-up of new technologies in line with our long-term growth priorities.

On the manufacturing front, Unitop commissioned additional ethoxylation capacity at Dahej, taking the total installed ethoxylation capacity to 66,000 metric tons per annum. This expansion enhances supply reliability and improves our ability to serve customer requirements more effectively.

At the same time, we are reviewing our broader investment plans across businesses in line with evolving business requirements and market conditions. We're also working to strengthen the operational backbone of the organization.

SAP S/4HANA implementation is helping create a stronger digital foundation across the business, improving visibility, coordination, and decision-making across functions. In parallel, we continue to advance our responsible manufacturing agenda through structured waste management and sustainability-led operational practices.

Overall, FY '26 has been a year of strong execution, capability building, and strategic progress. With a diversified portfolio, strengthened R&D capabilities, and expanding capacities, we believe we are well-placed to drive the next phase of growth in a more integrated, innovation-led, and scalable manner.

With this, I now invite Mr. Sunil Chari to share additional perspectives on our business performance and strategic priorities.

Thank you, Edward, sir, and a warm namaste to everyone. FY '26 was a year of steady progress for the company, and we are pleased to report a strong finish to the year.

Our performance during the quarter was broad-based, with all three business segments delivering healthy double-digit growth. A diversified portfolio and balanced exposure across end markets supported performance during the period, despite a dynamic operating environment.

From a segment perspective, HPPC delivered growth of 20% during the quarter, Textile grew by 10%, and AHN recorded a growth of 11%. This performance was supported by continued customer engagement, product development efforts, and steady execution.

Our focus remains on strengthening customer relationships, expanding the product basket, improving market penetration, and building scale in relevant chemistries and applications. On the export front, we witnessed continued momentum during the year with exports growing by 11% year-on-year in FY '26, supported by deeper engagement with existing customers and expansion into geographies across Latin America, Europe, Southeast Asia, and Africa.

Our focus on increasing wallet share with key partners and expanding into newer markets continues to strengthen our international business and diversify our growth profile. On the domestic side, demand conditions remained relatively soft during certain periods of the year.

Performance in the institutional and B2C businesses also remained subdued. As discussed earlier, we are actively undertaking cost optimization and portfolio rationalization initiatives in this segment.

On the international expansion front, we are making progress on our proposed initiative in the Kingdom of Saudi Arabia. As shared earlier, this remains an important strategic step towards strengthening our long-term manufacturing footprint and enhancing supply-side competitiveness.

In spite of the recent geopolitical developments, we remain confident of our Kingdom of Saudi Arabia expansion plans. At the same time, we remain watchful of the external environment.

The ongoing conflict in the Middle East has created uncertainty across raw materials markets, supply chains, and logistics, and this may have an impact over the coming quarters. While our Saudi initiative reflects a long-term strategic direction, our immediate focus remains on navigating the current environment through closer customer engagement, calibrated pricing actions, and disciplined execution.

Overall, we remain committed to building the business with a clear focus on growth and long-term value creation. The strategic steps we have taken across capacity expansion, portfolio development, customer relationships, exports, and international initiatives are steadily strengthening the foundation of the business.

We believe these efforts are putting the right building blocks in place to significantly accelerate growth over the next two to three years. As we move forward, our focus will remain on disciplined execution, strengthening our market position, and building a more scalable and resilient platform for future growth.

Thank you once again for your continued support, and I now invite Ketan to take you through the financial highlights.

Thank you, Mr. Chari, and good evening, everyone.

Let me take you through the financial highlights for the quarter and the year ended March 31, 2026. In Q4 FY '26, we delivered a strong performance, with revenue from operations at ₹684.9 crores, registering a growth of 18% YoY.

EBITDA for the quarter stood at ₹77.3 crores, up 11% YoY, with an EBITDA margin of 11.3% compared to 12% in the corresponding period last year. Notably, this quarter marked the company's highest ever quarterly revenue and absolute EBITDA performance.

For the full year FY '26, revenue from operations stood at ₹2,396.4 crores, reflecting a growth of 15% YoY. EBITDA for the year was at ₹286 crores, up 8% YoY, while EBITDA margins stood at 11.9% compared to 12.7% in FY '25.

The year's performance was supported by healthy growth across business segments, even as margins remained influenced by the prevailing cost environment. Gross margins during the period were relatively lower, with the quarter's sales mix having an impact on the overall margin profile.

Also, March saw some raw material price increases. Some of them were to the tune of 25% to 30%, which impacted the costs.

Some of our older orders for the quarter were also honored in the month of March. Some of these cost increases have since been passed on to the customers, and some of them are in the process of happening over the month of April and May.

That said, higher revenues along with disciplined cost management and operating efficiencies helped contain the impact at the EBITDA level. Our institutional and B2C businesses continued to operate in a challenging environment during the year, which had an impact on overall profitability.

We are taking calibrated steps to optimize costs and improve operational efficiencies in this segment. While growth in these verticals remained muted, losses have continued to moderate through the second half of the year.

This is driven by our focus on improving product mix, enhancing operational efficiency, and maintaining cost discipline. Excluding the institutional and the B2C businesses, our core B2B operations delivered an EBITDA margin of 14% for the year, reflecting the underlying strength and stability of our core business.

On the cost front, expenses remained elevated during the year, primarily on account of ongoing investments in capacity expansion, new business development, and capability building. As these investments scale up and utilization improves, we expect the operating leverage to support margin improvement over the coming years.

The other income during the quarter includes sales of our office space in Mumbai. The net income from this sales is ₹19 crores.

This is our first step towards liquidating some of our non-core assets. More of these we plan to do during this current year.

Our balance sheet remains strong with healthy liquidity and comfortable leverage levels, providing us flexibility to pursue our growth initiatives. We continue to focus on efficient working capital management and improving operational efficiencies across businesses.

In this step, we internally have decided to rephase our earlier capex spend, which was announced in April, of ₹192 crores across Rossari, Unitop, and Tristar. The reevaluation of this said investment plan is being done in light of the evolving business requirements and the market conditions.

As we move into FY '27, our focus will remain on improving capacity utilization, driving operating efficiencies, and scaling our growth initiatives in a calibrated manner. We also remain focused on enhancing margin profile through better product mix, operating leverage, and continued cost control, while maintaining a prudent approach to capital allocation and balance sheet strength.

That's all from my side. Thank you, everyone.

I would now request Mitesh to open up for question and answer.

Firstly, if you could tell us that what is the expectation shareholders should be having for FY '27, considering the Iran war and increase in raw materials and so on? What kind of growth are we looking at top line and what should be the consolidated operating margins that we are expecting?

Yeah.

Madhur, currently, as the situation is very dynamic, things are changing every day. For us, I think internally what we see and what we have planned is that our growth for the next year, we'll continue to do at least minimum the similar kind of growth that we've done in this year.

Hopefully, if things improve, our growth trajectory will be much better. We will have the new capacities now on stream for the full year and we are expecting the new EO capacities at Reliance to also come in the later part of this year, probably by Q3, that's what we have.

Currently, the way we understand, minimum we should be able to deliver this kind of a growth that we've done in this year. Anything if the situation globally improves, it'll only add on to our growth plans.

Sure. What about the EBITDA margins?

Yeah. Currently, the EBITDA margins will remain at these current levels, between 12% to 13%.

There are certain initiatives which we have planned for this year in terms of getting into some of better-margin segments like pharma, etc. Some of those will come into play probably by the second half of this year.

That should help us improve the margins. Currently, what we would like to put forth is the current margins will be maintained in the next year also.

Understood. Sir, if you could give us some idea about segment-wise margins broadly, like HPPC and textile specialty chemical and animal nutrition business, each of this business, what is the EBITDA margin profile?

No.

This is some data we don't put forth and we don't talk about it. To give you a sense of the margins, at the EBITDA level, most of these three businesses stay at the company-level margins.

Some of them could be slightly higher, a percent or two plus/minus, but generally they are at the same level. On the gross margin side, I can give you a feeler that textiles has a decent gross margin, AHN has higher margin, and HPPC, since it's a mix of both agro, non-agro, and other products, the gross margins are a mixed bag.

The cost profiles in each of these businesses, the fixed cost profiles are slightly varied. At the EBITDA level, they generally come out to be the company-level EBITDAs.

Okay. At least if you could give us some sense that which of these three divisions enjoys the highest margins and which enjoys the lowest margin, so that would be enough for shareholders to at least get a sense that, in future, if the mix changes, then what should be the impact on the margins?

That's where I'm coming from. Yeah.

At the gross margin levels, I think the smallest business segment of ours, AHN, enjoys the highest gross margin. Within HPPC, if you ask me, the agro and the oil and gas have better gross margins.

Pharma is a segment that we are going to start expanding from this year. That once that business becomes a reasonable size, is going to fetch us the highest gross margins across all these segments.

Okay. What about textile, is the lowest?

No,

textile again has a split of specialty and a little bit of the commodity chemicals. Within the specialty, textile margins are very healthy.

Sir, in each of these divisions, who would be our closest competitors?

As we have given in the past, in animal health and nutrition, there are global majors like Kemin, like Cargill, like Novus, what else, Vetnex, which was Pfizer, which has now become Zoetis. Then there are companies from Indian markets like Natural Remedies and Jubilant, who are there in the animal health and nutrition market.

In the textile, majorly we have Archroma, who also has a constant portfolio and the biggest portfolio as a leader. There are other multinationals like Croda, like CHT, and Pulcra.

In the home, personal care, and performance chemicals, in different segments we are different, but the global surfactant majors like BASF, Dow, Lubrizol, Sasol, Evonik, they are the players who rule the market globally. There are other companies like SABIC, who's Saudi Arabia, PETRONAS, who have integrated, but also Chinese companies are there.

The Indian market, there's imports coming from all the sources, but also some domestic players like India Glycols, which is there.

Understood. Sir, in textile chemical, there's a listed company, Fineotex Chemical.

Are they our competitors or it's a different business?

No, they also have textile chemicals and other specialty chemicals.

Is it like-to-like product portfolio or is it varied?

I cannot comment because I don't know their portfolio, yeah. Understood.

Sir, post this capex that is expected to get completed, what will be the peak revenue potential of the company? If we operate at full utilization across our manufacturing facilities across divisions, then what is the broad top line that we'll be able to achieve?

We should do an asset turn of at least three, between 3 to 4 at peak utilization.

Understood. Sir.

Thanks a lot. Sir, one last thing, sir, we are trading at less than 10 times EBITDA, which is a historical low, any plans to do a share buyback?

No, no, we have nothing like that on the cards.

Sir. Thank you very much and best wishes.

Thanks for the opportunity and good to hear the volume growth coming back. Two questions on the business side and a couple of them on the financial side.

First, in terms of sourcing of raw material, how much of our RM basket is crude-linked? In terms of sourcing, how are we currently placed both from acrylic acid and EO, which are again crude-linked?

Lastly, in terms of domestic and international sourcing, how does that also look like? Thank you.

Namaste, Rohit. This is Sunil Chari here.

Currently, our raw material position looks to be stable. Our supply chain teams have been able to maintain all the raw materials.

We do not have stock shortages of any raw materials. Ethylene oxide supply also is very stable.

We have no worries on that. Raw material prices have gone up, and raw material prices we have been able to pass through in the current marketplace.

Ethylene oxide is made domestically, we have no imports. As we do not have too much imports of our raw materials.

Whatever raw materials are there, phenol is available from various sources, including Thailand, including Malaysia, including India, and including China. We are not buying anything from the Middle East now, but there's also a lot of material coming from US, which does not pass through the Strait of Hormuz.

Then there is similar other raw materials like acetic acid, which has plenty of other sources. We have silicones which come in from China.

Acrylic acid is something which India manufactures, and it comes from various sources. Unlike other industries, our dependence on Middle East is not as much as the other countries.

Of course, prices globally have risen, and last quarter, last month especially, we had to buy some raw materials at higher prices because we had orders from the customers and that impacted our gross margins. From this month onwards, we've been able to pass through all our high-priced raw materials into adding margins and getting the final prices.

The customers are accepting because everybody can see the global geopolitical situation. Going forward also, I don't foresee any issues on RM sourcing and availability for the range of raw materials which we buy now.

Sure. Sure, that is helpful.

Second question in terms of just to understand the postponement of capex. It was exactly one year back we had announced we were supposed to commission it now.

Why such a late announcement in terms of postponing it? What has been the main factor for reconsidering it?

Thank you.

Rohit, on the capex front, I think you've seen that we had kind of delayed that, the ethoxylation capacities which were also supposed to come year before last. Then Reliance again redid its plan for capacity expansion, and hence we also slowed down in that capex spend.

That capacity we have capitalized now partly in Q3 and the balance now in Q4 in the month of March. The other capex plan which we had announced in the April of last year, which had a mix of products in the amine range as well as some pilot plant, some R&D expansion at the sites, some of them, because of the earlier capex getting a little delayed, even this capex we decided not to immediately go and start spending on this, keeping in mind the current business requirement and the overall global situation that's prevailing.

Also, the spend which we had planned for the R&D at sites, we went ahead and we've now set up this new R&D facility at Navi Mumbai. Probably our R&D needs we plan to get it accomplished from here itself.

Some of the other smaller products and amines that we had planned, I think it's not that we've decided not to go ahead with this. We'll probably now rephase this entire spend over this year and partly next year.

That is something which we are internally still planning out that how we should plan out this spend, because that total spend was also to the tune of ₹190 crores, if you add up at all the three sites. A little bit of change in our strategy and also the business environment.

This spend will happen. These are new products which we are working.

Some of them we'll definitely do this year because there's a part work on one of the pharma products also, so that will surely come up sometime in this year. Some of the other spends probably we will relook and rephase it.

It's just a more optimization of our spend in terms of cash flow management and the ratios that we are looking, ROCEs, we would like at least the current capacities to give back some of the returns that we had earmarked and then probably go ahead and spend on these balance capexes. That's what was the thought.

Since we thought it was prudent that we talk to the investors and everyone about this.

Just one allied question on that. In terms of capex, what is the number that we are looking this year?

Current, what is the gross debt, including the long-term as well as working capital? Given that the capex plan is now mellowed down, we will be looking at paring off the debt in the next one year, 1.5 years?

Thank you. Yeah.

The capex plan for this year would be, I think, anything between ₹50 to ₹75 crores. That is the plan.

We would not like to spend anything more than that. That also at very peak level we would reach that ₹70, ₹75 crore number.

In terms of the debt that we have now, almost we have ₹200-odd crores, I think, of long-term debt, and the balance is the short-term working capital borrowing. Some of the other plans that we have in this year, one, of course, to use the cash flows to bring down the overall debt levels.

Secondly, also to shed off some of the non-core assets that are there in the books. One we already did in the last quarter, which was the office space at Mumbai.

We have a couple of more office spaces here and some more assets across India which we are currently not utilizing. We'll try to get rid of all these non-core assets.

There are some further plans which we have in terms of trimming our product profile, business segments. Some of them we plan to bring it on ground in this year.

All these we expect will help us improve our cash flows and prune down the overall debt, probably by the end of this year. That's what the plan is, that this year and probably in another 18 months, we should be able to bring down our debt significantly.

The target is to actually get debt-free in the next 18 months, but I think that the time will say, but currently the plan is to keep bringing down our debts over the next 18 months.

Sure, that is helpful. One more last question in terms of current ethoxylation, after the 66,000 tons, what is the utilization level that we are currently working on?

In terms of the ethoxylate product, how has been the response from the customers given that the pricing, raw material prices have gone up and consequently the product prices have also gone up? How comfortable are the customers to pay for it?

Or is there any demand-side challenge which may emanate if not now, maybe a month, couple of months later? Thank you.

There's no demand-side challenge. Orders remain robust.

The agro season is dependent on El Niño. The El Niño effect can affect the agro season.

It's too early to comment, but we had worries last year also, but nothing much has materialized. Other than that, the global situation, we don't see any fall in demand.

We see a good pipeline of projects which our sales teams and business development teams have worked on in the last 12 months, and we should be able to see results from those initiatives. The utilization level for ethoxylation currently?

Utilization level for ethoxylation is practically 90% to 100%. What all maximum we can do, we run 24x7 days, 365 days a year, and apart from what all it gets stopped for expansion, we don't have a single downtime in anything.

We have added into new expansion capacities. We are confident that Reliance will release more EO from December when their expansion is done for the partial expansions, and because more is coming up in next December, that is what is the plan.

We should see availability of EO, and we have the capacities, and we think the market is also there.

Sure. Thanks for answering all the questions and all the best, sir.

Hello. Good afternoon.

Am I audible?

Yes, Maitri. Please continue.

Hello. I have a couple of questions.

Firstly, you mentioned that we are doing around ₹50 to ₹70 crore capex for FY '27, and part of it is going for the pharma facility. Any other capex are we adding other than the pharma facility for this year?

Apart from the pharma facility, we are going to do a couple of small capexes. One of them is probably going to be in the aroma chemicals space.

These are the two we have at least now concluded that we should do it in this year, then these two are the big ones. Big ones in the sense in that number of ₹50 crores.

Okay. Secondly, on the pharma side, you mentioned that our margins are the gross margins are the highest among them all.

What exactly are we targeting in pharma? Do we have a clientele base on it?

How are we going to expanding the pharma portfolio from now on?

See, amongst all our chemistries, we have surfactant, we have acrylic, we have enzyme, and we have silicones. All of these can go into the pharma.

Presently, our focus is on the surfactant chemistry. Our polyethylene glycols, but there are a host of other products.

Polyethylene glycol comes in different molecular weight. For example, we sell polyethylene glycol from 400, 600, 1,000, 2,000, 3,350, 4,000, 6,000, 10,000, 20,000, and above.

All these are areas which can go into the pharma. There are also other esters which we manufacture which can go into pharma.

The focus would also be on coating products, but also something like products which can make gels for pharma and personal care. These are products which we focus on the pharma.

That's great. Secondly, on the margins, we've guided for a 12% to 13% margin on a consol basis, but we've seen the margins kind of drop quarter-on-quarter this year for FY '26.

You did allude it for that kind of a mix change we had, we also had raw material price increase. What sort of kind of initiatives are we taking on supporting the EBITDA margins right now?

How confident are we on maintaining this 12%, 13% guidance for FY '27 and also for the next year for FY '28?

See, this year, we have one initiative is selling some assets and selling some businesses which are not core to our businesses or which requires a lot of investment to grow those businesses, especially the consumer businesses that are pulling down our gross margins and our EBITDA margins. Once these businesses are not there in Rossari, automatically our margins will improve.

The second part is now we're focusing on value-added products, products that are higher margins, and consciously cutting down on low-margin products. This should also help us increase the margins.

The focus on food, personal care, pharma, cosmetics, and also animal health and nutrition, these are all high-margin areas which we want to focus on. We have the products, we have the approvals, and we see a gradual increase in both the gross margins and EBITDA margins.

Okay. Any sort of metric you can kind of provide us with what sort of value-added sales we have for FY '26, maybe from next quarter onwards, we could kind of track on how we're growing on that number, if that's possible?

We would not like to share so much of details,

but

we'll think about this, how we can give a little more info on the data that we currently provide in the presentation.

Okay. Our core B2B business has close to 14% EBITDA margin.

What sort of revenues are they contributing to? How do you see that kind of scaling up?

Because once that kind of business grows, we can see on a consol basis a quite higher margin going forward.

Yeah. Most of the growth that we've discussed now are all going to happen in our core B2B business.

On the consumer side of the business, we are, in fact, relooking at the entire business and the product profile in that business. There also we are trying to ensure that we only work on products where the margins are stronger.

That's what the plan is. Yes, most of this growth that we talked about is all going to happen in our B2B business.

What raw percentage of revenue is contributed from this B2B business currently, FY '26?

₹250 crores. Yeah.

Say you can from the total, you can subtract about ₹250 to ₹260 crores of B2C business, balance everything is a B2B

business.

Even in the presentation, you can have a look.

Okay. On the revenue side, how you mentioned that at least we're going to target 15% growth for FY '27 as well, but any new drivers that you expect kind of increasing or reaching up the growth to the higher side of the double digit, like 20% growth moving forward, if you could mention those?

Yeah. As I said, the capacities that we have put up in FY '26, we'll have this for at least for more than half the year next year, assuming the EO availability also comes through by the second half.

Then, of course, the segments that we are looking at are the pharma, the agro, these two are going to be the current segments which are going to drive the growth, and the new segments of pharma that we are planning to get into. That will also add, though may not add a big number, but it'll help us at least penetrate the market for the coming years.

Thirdly, the oil and gas is another segment that's going to drive growth in the current year. These three, four initiatives will help us drive the 15% plus growth that we talked about.

That's great. The cost-cutting kind of initiatives that we mentioned before that we are taking in effect from next year, could you elaborate on that, how the quantum of benefits that will happen over the next two to three years, if that's possible to quantify?

Cost-cutting in the sense see, we've already in this year spent a lot of cost in terms of employing talent. If you see our employee costs have gone up significantly in FY '26, if you compare it with the earlier years, but that was a sort of an investment which we did willingly given our plans for expansions in the next few years.

Hopefully, the employee cost expense will not grow at similar levels, though we'll be taking in some new talent also, but not at the same kind of numbers. Apart from that, as Mr.

Chari also said, we'll be moving out of a lot of our non-core businesses. We are evaluating how we should restructure our business segments, some of these consumer-focused business which really we are not able to give the kind of time, energy, money that they require for their growth.

If we can cash out of these businesses, then I think it'll help us streamline our core business, and it will also help these businesses to take their own path of growth with whoever comes in. This is something which we don't have anything concrete as of now,

but these are some

of the things that we are looking at

so

that we can keep growing on in our core business.

Sure. The consumer-focused business, what sort of asset block does pertain to that kind of vertical right now?

Are we going to is it fungible? Are we going to move it to the B2B side, or are we actually going to be selling out a lot of the non-core assets?

If you could quantify what amount of assets we have planned to sell out?

No. They do not account for too much of our asset block.

Most of our asset blocks

are for the B2B businesses. These are only add-on blocks that we had which we carved out of our B2B segment assets to do some of these consumer products.

They don't account for too much of our asset block.

Any quantification of how much is the value we're going to be selling?

I would not have offhand this number.

Fine. That makes sense.

The Thailand textile facility, how has that been going on? Did we record any revenues in the fourth quarter?

What sort of guidance would you give on the revenues that we can realize from FY '27?

Yeah. Thailand plant has come on stream in the last quarter towards the end of March.

It's a small blending unit that we've set up. It's not a full-scale textile chemical plant.

The plan is to do some blending in Thailand to meet the customer requirements of Southeast Asia. Also the plan is that some of the raw materials for our blending activities, we can bring in directly there from China at more competitive rate.

Thailand is going to now start contributing meaningfully from this year, probably from the Quarter 2 onwards we should see meaningful ramp-up in the Thailand facility. It will start off with textile.

We'll do a little bit of AHN also, that's the plan. Then we'll see how it ramps up, how the customers react to the products from there.

Then probably we will think of adding some more products within our other basket of home and personal care also.

That's great. The peak revenue that you can kind of gauge from the Thailand plant currently is how much?

Hello?

Yeah. We should do about, I think, between ₹50 to ₹75 crores at its peak, depending on, since it's blending, it depends a lot on the product also and what kind of blend we do.

We can do at a peak ₹50 to ₹75 crores of revenue.

This will be over and above the 15% growth that we're targeting for FY '27?

No, no, this is all inclusive of that. We will not reach ₹50 crores in this year itself.

That is sure,

but

the Thailand revenues are inclusive in the 15% growth, right?

Yes, they are all part of this 15%.

Okay. Fine, that is it from my side, sir.

Thank you.

Hi, team. Thank you so much for the opportunity.

My first question is on the pass-through that we were able to do in March, some of it, and some of it will be in April and May. Can you outline is there any challenge in any particular segment in pass-through, or is it broad?

No, there is no challenge. We have been able to pass it through from the 1st of April.

Pass-through is easy for all the products. We have some resistance in textile industry, but we are controlling the supplies and ensuring that we do at profitable margins every business.

All right. Just one on the capacity related.

The 15,000 tons in Unitop, which was commissioned in Q2 FY '26, so that capacity was roughly around 10% to 15% utilization in Q3. What's the current utilization that was done on Q4?

It is a little more, better than Q3. We do not have the exact figures.

I do not have exact figures now. It is ramping up.

Everything is ramping up more.

The growth that came in for the subsidiary, Unitop, in Q4, that's largely on the higher utilization of that capacity, right?

Perfect, yes. Correct.

Okay. There was a premix plant that was supposed to come up in Q1 FY '27.

Are we still doing that in the same timeline or is that also delayed?

No, no, that's as per its timeline. It'll come up probably by end of this month.

It's commissioned. That's already been commissioned, yeah.

The revenues

coming from the premix starting this quarter. All right.

Okay. All right.

Yeah.

Okay. That's from my side.

Thank you so much.

Hi, sir. Hello?

Yeah. Yes, we can hear you.

Sir. Sir, I was asking what is the percentage of revenue that we generate from our top 10 customers?

We would be doing between 12% to 13%, not more than that. Our products are very well-diversified, the concentration is very less.

Our top 10 customers would not would be, I think, between 12% 12%-ish is what I I have offhand number.

We do not have any customer which is more than 2% of our sales. We now have very good diversification in terms of customers.

Sir,

what percentage of our customers are coming back to us? Repeated customers.

Sorry, what was your question? What percent

What percentage of our customers are are repeat customers basically?

Repeat customers, practically, we have been growing. For example, if you see in the last six years, we have grown 25% CAGR in sales, and we have grown 18% CAGR in profits.

That would majorly come from repeat sales, but also getting new customers, but also getting new products into existing customers. Getting a bigger wallet in every customer is something which we always target.

Right, right. Perfect, sir.

Thank you.

Hi. What explains the difference between the stand-alone and consolidated profits in this quarter?

The stand-alone profit seems to be higher than the consolidate number.

I don't think you should see the number separately. It is better to see it at a consolidated level, because now the business mix is such that we sell similar products from subsidiaries to certain customers, the same products to certain customers from Rossari.

Most of the sales currently is happening out of the Rossari company, because Rossari is the registered supplier for most of the customers in India as well as globally. Hence, while some of the products are manufactured at the subsidiaries, some part of their end blending could happen in Rossari and vice versa.

That mix between stand-alone and consolidated could keep changing quarter and quarters. The best way to look at the performance is at the consolidated level.

Got it. Would you like to probably give a timeline or a rupee value amount of divestment of non-core assets?

Just a ballpark ranges is fine.

No, we would not like to hazard any numbers. See, this is something which we are still internally working on.

At an appropriate time when we have something on hand, we will come back and talk about it.

The divestment will happen in FY '27?

No, that also we cannot give you any timelines. The plan is we would like it to happen in '27, but it could take more than in a year, 2 years.

My aim of talking about it was strategically we are looking at getting out of these non-core businesses. It could take its own time.

We should get a proper value for the business. We've built this business over the last so many years, we would like to exit it at a good value and exit it to a customer who would be able to grow this business, because this business have a lot of inherent strength to grow.

Okay. Just need one clarification from the promoter.

There was some rumors of promoter kind of selling some stake or exiting the entire company on the new share somewhere in the month of Jan and Feb. Any clarification on the same?

I think there is nothing of such at all. Here, we are all sitting, working, and focusing on growth.

Market rumors will come and go. There is nothing on the plan at this moment.

Got it. Thank you and all the best.

Thank you for the opportunity once again. Sir, it seems that our B2C business is loss-making currently.

What kind of working capital requirements have we invested in this business on the ₹250, ₹260 crore revenue that we have currently?

It would have similar kind of working capital, the kind we have in the company. Net working capital would be close to 90-odd days in this business.

Got it. Sir, it seems that on a revenue potential basis, we could do ₹3,500 crore on our current asset base.

How should we see the ramp-up maybe over the next 3, 4 years? Will it be driven by customer addition or will it be driven by the solution that we are trying to move towards pharma, oil and gas, these solutions?

Although scale-up might take time due to this high-margin segment, but whatever incremental revenue will come will be a better margin. How should I look at that segment?

You're talking about growth as a company level or growth in pharma segment?

Sir, I'm talking about the growth at company level, but what I understood from this call was we are trying to move towards more value-added products going forward. A lot of incremental growth will come from these pharma, oil and gas, these kind of segments.

I'm trying to understand on that front.

Not only the pharma or oil and gas, there's aroma, there's personal care, and there is food processing, and there is institutional chemicals, cleaning chemicals for health and hygiene. It will be spread across different segments, but also animal health and nutrition could be a good driver for our increased margins.

Our focus remains now on getting into a higher orbit for the EBITDA. The teams are being attuned, trained, made to focus that each businesses we have to improve our return on capital employed and EBITDA margins.

Right. Sir, on the ramp-up front, it seems that these businesses will have a higher gestation period versus our current customer, where you're already a qualified vendor.

Sir, I'm trying to understand how should I look from a gestation period perspective for ramp-up towards optimum utilization of our capacities?

The expectation is that ramp-up will happen over the next two to three years. While we will be getting into some of these higher-value-added segments, our current segments of core agro and textile and AHN will keep seeing their latent growth happening parallelly.

Even in personal care, the phenoxy business where we are one of the largest globally, and with the new capacities coming up, we are getting into newer markets across the globe. The North American market we are looking at both for the personal care and the agro business.

In the Latin America, we are already strong in agro, we're trying to build the business there. Again in textiles, we are ramping up our exports business.

Bangladesh, the Southeast Asian countries through Thailand, and also Turkey, Brazil, these are some of the markets within textiles where we expect the export growth to outperform our domestic growth in textile. Similarly, AHN with this new premix facility coming up, we should see this part of this ramp-up happening this year and a full-scale premix facility capacity enhancement in the next year.

All these, I think, plans that we have on the table, I think that's what makes us pretty bullish on that at least a minimum 15% growth coming in FY '27.

Right. Sir, thank you so much and all the best.

Thanks for the follow-up. Just one clarification on the institutional business.

We've been feeding this business, but FY '26 performance has been relatively muted with expanding losses. How are we looking at it in terms of scaling up and when do we now expect break-even happening?

Is it going to be FY '27, '28? Any timelines on that?

Thank you.

FY '27, we should look at break-even or even profits, and also divestment of some businesses in that business which are lower margins or which contributed to the EBITDA loss. We feel '27 should be a very good year for the institutional business.

Sure. That's all from my side.

Thank you so much and all the best.

Thank you, everyone. I hope we have been able to answer all your questions satisfactorily.

Should you need any further clarifications or would like to know more about the company, please feel free to contact our team or CDR India. Thank you once again for taking the time to join us on this call, and good evening.